ライフサイエンスコーパス: SCr

1 SCr at 12 months was 1.6+/-0.7 in group 1 and 1.8+/-1.0

2 SCr decreased by 1.1 mg/dL in patients receiving terlipr

3 SCr in reversible AKI returned to baseline </=48 h after

4 SCr increases > or = 0.5 mg/dL occurred in 4.4% (9 of 20

5 SCr level improved from baseline to day 14 on terlipress

6 SCr level in the early postischemic period (24-72 hr) se

7 SCr levels after contrast material administration are lo

8 SCr values probably underestimate the degree of kidney f

9 SCr values were not statistically different late posttra

10 SCr-based and CrC-based scores were similar between grou

11 39 unique patients associated with 1,510,001 SCr values were identified.

12 dence of HRS reversal (defined as at least 1 SCr value </=1.5 mg/dL while on treatment), transplant-f

13 tions between renal function (estimated by 1/SCr and 1/CysC) and SBI, controlling for potential confo

14 rithmic GFR from the following covariates: 1/SCr, 1/SCr2, age, and sex (where SCr = serum creatinine)

15 imated by the inverse of serum creatinine (1/SCr); moderate renal impairment was defined as SCr > or

16 [CI] 1.09 to 1.32; P < 0.001) but not for 1/SCr (OR 1.08; 95% CI 0.98 to 1.19; P = 0.14), for which

17 Similarly, a 0.5-unit decrement in 1/SCr (equivalent to an increase in SCr from 1.0 to 2.0 mg

18 d by a flattening or positive slope of the 1/SCr plot and no graft loss.

19 ted with SBI (OR 1.26; P < 0.001), whereas 1/SCr was not (OR 1.06; P = 0.3).

20 Estimates based on 100/SCr and the new equation were the most precise.

21 fidence interval {CI}: 0.65, 1.86], P = .70; SCr >/= 0.3 mg/dL or 50% over baseline AKI definition od

22 rease or GFR decrease for 3 days after CT, a SCr increase (of >or=0.5 mg/dL [44.2 micromol/L, 25%] or

23 e of AR, as 32% of patients in group 4 had a SCr at 10 days after transplantation (SCr(10d)), before

24 No patient developed abnormal SCr levels (> 1.6 mg/dL [141 mumol/L]) as a result of th

25 from 2011 through 2013 who had an admission SCr value were included in this study.

26 The U-curve relationship between admission SCr and respiratory failure during hospitalization was o

27 risk related to markedly elevated admission SCr of >=1.5 mg/dL (OR 1.61; 95% CI 1.39-1.85).

28 ted with both reduced and elevated admission SCr.

29 Of these patients, 799 (1.1%) had admission SCr of <=0.4 mg/dL, and 2886 (4.3%) developed respirator

30 justment for confounders, very low admission SCr of <=0.4 mg/dL was significantly associated with inc

31 5 eligible patients, with the mean admission SCr of 1.0 +/- 0.4 mg/dL, were studied.

32 um creatinine (SCr; peak SCr minus admission SCr) and categorized as no AKI (SCr change, <0.3 mg/dL),

33 spiratory failure based on various admission SCr, using SCr of 0.7-0.8 mg/dL as the reference group i

34 of AHR, serum creatinine (SCr) level at AHR, SCr level after PP and IVIg at 3 months, days to achieve

35 s no AKI (SCr change, <0.3 mg/dL), mild AKI (SCr change, 0.3-<0.5 mg/dL), moderate AKI (SCr change, 0

36 (SCr change, 0.3-<0.5 mg/dL), moderate AKI (SCr change, 0.5-<1.0 mg/dL), and severe AKI (SCr change,

37 us admission SCr) and categorized as no AKI (SCr change, <0.3 mg/dL), mild AKI (SCr change, 0.3-<0.5

38 The incidence of AKI (SCr >/= 0.5 mg/dL above baseline) was compared between c

39 SCr change, 0.5-<1.0 mg/dL), and severe AKI (SCr change, >/=1.0 mg/dL).

40 econdary endpoint was defined as reaching an SCr value greater than 1.6 mg/dL.

41 <45, <30, 30-44, 45-59 mL/min/1.73 m(2)) and SCr (<1.5, >/=1.5, >/=1.6, >/=1.7, >/=1.8, >/=1.9, >/=2.

42 vations occurred in 10% vs. 4% (p=0.28), and SCr elevations occurred in 20% vs. 6% (p=0.06) of patien

43 Late-exposed rabbits had elevated BUN and SCr relative to early-exposed.

44 and TFF3 augmented the potential of BUN and SCr to detect kidney damage.

45 The CysC definitions and SCr definitions were similarly associated with clinical

46 0 mg/dL, those with SCr 1.0 to 1.4 mg/dL and SCr >1.4 mg/dL had an increased hazard ratio of death (u

47 Renal oxygenation, eGFR, and SCr improved after MT + PTRA.

48 g of molecular markers of tubular injury and SCr data.

49 The LFT and SCr elevations were not attributed to RDV in either grou

50 LFT and SCr elevations were not attributed to RDV in either grou

51 iscrepancy between kidney injury markers and SCr level can be reconciled by the recognition that many

52 ham surgery was induced in C57BL/6 mice, and SCr level and inulin clearance (Cin) were measured betwe

53 n adults) across the FAS (2 to 90 years) and SCr range (40 to 490 umol/L [0.45 to 5.54 mg/dL]) and wi

54 r); moderate renal impairment was defined as SCr > or = 1.3 mg/dl for women and > or = 1.5 mg/dl for

55 h all had substantial effects on the average SCr levels at discharge.

56 Baseline SCr may be misestimated in severe trauma patients becaus

57 itus, use of N-acetylcysteine, mean baseline SCr, and estimated glomerular filtration rate were compa

58 ial pressure correlated weakly with baseline SCr (r = 0.165, p = 0.03).

59 Because SCr is also a function of muscle mass, the authors deter

60 ile of CysC, whereas the association between SCr and SBI was U-shaped, with greater prevalence at hig

61 , we found a significant interaction between SCr and right atrial pressures (interaction P<0.0001); i

62 there was a significant relationship between SCr 6mo in paired recipients (P < 0.0008 by Spearman).

63 determined whether the relationship between SCr and dementia was particularly strong among individua

64 gnostic performance of urinary Kim-1 to BUN, SCr and urinary N-acetyl-beta-D-glucosaminidase (NAG) as

65 in these patients, which was not detected by SCr or estimated GFR alone.

66 d to have similar rates when reclassified by SCr levels at discharge.

67 ntrast material-induced nephrotoxicity (CIN; SCr increase >/=0.5 mg/dL [44.20 mumol/L] or >/=25%).

68 Iothalamate clearance, SCr, and creatinine clearance were obtained at each visi

69 eGFR <45 mL/min/1.73 m(2) instead of common SCr thresholds would significantly increase the number o

70 patients with prepregnancy serum creatinine (SCr) >150 micromol/L, a trend toward increased postpregn

71 ow a 6-month baseline of 1/serum creatinine (SCr) (slope of reciprocal creatinine) at or beyond 1 yea

72 ssure (BP), lipid profile, serum creatinine (SCr) and albumin-to- creatinine ratio (ACR)), types of d

73 oxicity in animal systems, serum creatinine (SCr) and blood urea nitrogen (BUN) are the primary optio

74 ed survival at seven days, serum creatinine (SCr) and blood urea nitrogen (BUN) daily for 3 days, and

75 Serum creatinine (SCr) and blood urea nitrogen (BUN) levels were evaluated

76 ent preclinical biomarkers serum creatinine (SCr) and blood urea nitrogen (BUN).

77 markers of renal function: Serum creatinine (SCr) and cystatin C (CysC).

78 ) is defined by changes in serum creatinine (SCr) and diuresis with risk/injury/failure/loss/end stag

79 iltration rate marker than serum creatinine (SCr) and may improve AKI definition.

80 inpatients with sufficient serum creatinine (SCr) data and stable renal function (difference between

81 inpatients with sufficient serum creatinine (SCr) data were identified.

82 g 9210 who had two or more serum creatinine (SCr) determinations, was evaluated.

83 n 10% vs 4% (P = .28), and serum creatinine (SCr) elevations in 27% vs 6% (P = .02) of patients with

84 of death, or pre-retrieval serum creatinine (SCr) greater than 1.5 mg/dl.

85 RD) performance to predict serum creatinine (SCr) in severe trauma population and determined the best

86 nvestigate the validity of serum creatinine (SCr) level as an indicator of postischemic renal dysfunc

87 dose of IVIg, time of AHR, serum creatinine (SCr) level at AHR, SCr level after PP and IVIg at 3 mont

88 as doubled on day 4 if the serum creatinine (SCr) level did not decrease by 30% of baseline.

89 pe 1 or type 2 diabetes, a serum creatinine (SCr) level of 1.3-3.3 mg/dl for women and 1.5-3.5 mg/dl

90 crease in maximal observed serum creatinine (SCr) level of either (a) >/=0.5 mg/dL (44.2 mumol/L) or

91 for CIN by using baseline serum creatinine (SCr) level.

92 n 228 patients with normal serum creatinine (SCr) levels (< or = 1.6 mg/dL [141 mumol/L]).

93 Serum creatinine (SCr) levels (mg/dl) were similar in all three groups at

94 57), elevated preoperative serum creatinine (SCr) levels (OR 1.02; 95% CI 1.01, 1.03), transition fro

95 Serum creatinine (SCr) levels and estimated glomerular filtration rate wer

96 od urea nitrogen (BUN) and serum creatinine (SCr) levels were measured.

97 ney function and available serum creatinine (SCr) measurement before and after imaging who underwent

98 ensitive and specific than serum creatinine (SCr) or blood urea nitrogen (BUN) in monitoring generali

99 by percentage increases in serum creatinine (SCr) over baseline.

100 Mean (SD) serum creatinine (SCr) to BMI ratio was higher in both anorexia groups com

101 he association between low serum creatinine (SCr) value at admission and the risk of respiratory fail

102 t function was assessed by serum creatinine (SCr) values collected at early (mean, 50 days) and late

103 Daily (0-18) serum creatinine (SCr) values during and after the AR were plotted for eac

104 Mean discharge serum creatinine (SCr) values were computed after excluding patients who d

105 The mean discharge serum creatinine (SCr) was 2.7 (+/-2.5) mg/dl in the SCN recipients compar

106 Serum creatinine (SCr) was determined on entry into the study (initial PAH

107 jection (AR), and 12-month serum creatinine (SCr) were examined.

108 Replacing serum creatinine (SCr) with estimated glomerular filtration rate (eGFR) in

109 dge of an optimal expected serum creatinine (SCr) would be useful to detect early renal dysfunction a

110 raft function, measured by serum creatinine (SCr), after pregnancy in KT recipients, stratified in ye

111 bilization or reduction of serum creatinine (SCr), as evidenced by a flattening or positive slope of

112 en found to associate with serum creatinine (SCr), estimated glomerular filtration rate (eGFR) and/or

113 splant monitoring included serum creatinine (SCr), peripheral T-regulatory cells (pTregs)(127/CD4+/25

114 ated with changes in eGFR, serum creatinine (SCr), systolic blood pressure (SBP), renal hypoxia, and

115 for adults are recommended serum creatinine (SCr)-based calculations for estimating glomerular filtra

116 ., iothalamate clearance), serum creatinine (SCr)-based GFR estimates, or creatinine clearance.

117 ar injury and elevation in serum creatinine (SCr).

118 ctive variables, including serum creatinine (SCr).

119 es (DSA) and acute rise in serum creatinine (SCr).

120 ted by similarly increased serum creatinine (SCr; approximately 4.5 mg/dl) at 2 days, tubule necrosis

121 using absolute changes in serum creatinine (SCr; peak SCr minus admission SCr) and categorized as no

122 nction (WRF) (upward arrow serum creatinine [SCr] >or=0.3 mg/dl) during treatment of decompensated HF

123 Incidence of AKI (serum creatinine [SCr] increase of >/=0.5 mg/dL [>/=44.2 mumol/L] above ba

124 ersal (CHRSR, defined as 2 serum creatinine [SCr] values </=1.5 mg/dL, at least 40 hours apart, on tr

125 ths after transplantation (serum creatinine [SCr]6 mo) and donor variables (P = 0.0004, analysis of v

126 This effect strengthened as pre-CT SCr increased.

127 ment of post-CT AKI for patients with pre-CT SCr levels of 1.6 mg/dL (141.44 mumol/L) or greater (odd

128 tion (difference between baseline and pre-CT SCr within 0.3 mg/dL and 50% of baseline) were identifie

129 s, and it increased with increases in pre-CT SCr.

130 Iodixanol decreased SCr (mean +/- standard deviation) from 1.77 mg/dL +/- 0.

131 Only within 2 years postpartum Delta SCr was marginally higher (0.18 mg/dL, 95%CI [0.05-0.32]

132 Only within 2 years postpartum, Delta SCr was marginally higher (0.18 mg/dL, 95%CI [0.05-0.32]

133 In patients with diabetes, SCr increases > or = 0.5 mg/dL were 5.1% (4 of 78 patien

134 and with published guidelines (>/=2.0 mg/dL [SCr] and <45 mL/min/1.73 m(2) [eGFR]) using McNemar and

135 endpoints demonstrated similar results (eg, SCr >/=1.6 mg/dL [141.44 mumol/L] by using traditional C

136 Albumin outperformed either SCr or BUN for detecting kidney tubule injury and TFF3 a

137 Elevated SCr was associated with higher right atrial pressure and

138 An elevated SCr 6 mo was significantly associated with older donors,

139 However, an elevated SCr(10d) correlated with other potential risk factors fo

140 oth the donor and recipient, and an elevated SCr(10d) predicts a higher risk of acquiring additional

141 6), patients without AR but with an elevated SCr(6mo) (group 2, n=117), and patients with AR but low

142 ly worse in patients with AR and an elevated SCr(6mo) (group 4, n=165) compared with patients in the

143 The elevated SCr(6mo) in group 4 patients was not necessarily the con

144 linically indistinguishable with established SCr-defined criteria, suggesting that intravenous iodina

145 ulated MDRD equation is supposed to estimate SCr using a predetermined GFR of 75 mL/min/1.73 m.

146 Proportion of estimated SCr values that deviated less than 15%, 30%, or 50% was

147 Expected SCr correlated with the observed SCr in both living and

148 ed a formula to predict the optimal expected SCr after transplantation derived from donor and recipie

149 We compared the expected SCr with the lowest observed SCr in a cohort of living (

150 While more of patients with SRI experienced SCr elevations, 3 (75%) patients had acute kidney injury

151 percentage of patients with SRI experienced SCr elevations, 3 (75%) patients were in AKI prior to RD

152 nfidence interval 1.73 to 3.71, P<0.0001 for SCr >1.4 mg/dL).

153 nfidence interval 1.26 to 2.17, P<0.0001 for SCr 1.0 to 1.4 mg/dL; unadjusted hazard ratio 2.54, 95%

154 ed AKI, and 0.66 and 0.58, respectively, for SCr-defined AKI.

155 2.04 (95% CI, 0.94-4.38), respectively, for SCr-defined AKI.

156 minated for CysC-defined AKI better than for SCr-defined AKI.

157 monly used equations for estimating GFR from SCr levels.

158 en the solitary and bilateral kidney groups (SCr >/= 0.5 mg/dL AKI definition odds ratio = 1.11 [95%

159 sed thresholds: 92.6% (26 285 of 28 390) had SCr <1.5 mg/dL; 91.3% (25 922 of 28 390) had eGFR of >/=

160 .5%) than in the iopromide group (27.8%) had SCr increase 0.5 mg/dL or higher (>or=25%, P = .012).

161 Two patients in each group had SCr increase of 1.0 mg/dL or more (not significant).

162 regnancy proteinuria, hypertension, and high SCr are risk factors for GL.

163 pregnancy proteinuria, hypertension and high SCr are risk factors for GL.

164 rate renal impairment, reflected by a higher SCr, is associated with an excess risk of incident demen

165 Among those in good-excellent health, higher SCr was associated with vascular-type dementia but not A

166 atients, but there were significantly higher SCr increments among group III patients after the 1 year

167 ctive IgG AECAs and had statistically higher SCr values and incidences of cellular rejection early po

168 However, SCr remained elevated compared with preischemia-reperfus

169 ts in the ED suggests that dynamic change in SCr among patients with AKI was associated with hs-cTnT

170 Dynamic change in SCr during the ED visits.

171 We assessed a change in SCr from baseline to 12 months as the primary efficacy v

172 Least squares mean percentage change in SCr from baseline to end of treatment did not differ bet

173 The placebo group had a mean+/-SD change in SCr from baseline to end of treatment of 0.33+/-0.67 mg/

174 nitial, defined as the incremental change in SCr from baseline to first postoperative measure.

175 igher in the highest vs the lowest change in SCr quartile (64.7% [95% CI, 58.4%-71.5%] vs 36.3% [95%

176 cTnT >14 ng/L) in association with change in SCr, and to assess the diagnostic performance of hs-cTnT

177 e of > or = 25%, and the mean peak change in SCr.

178 The percentage changes in SCr after severe AKI are highly dependent on baseline ki

179 of AKI that incorporates absolute changes in SCr over a 24- to 48-h time period.

180 Modest changes in SCr were significantly associated with mortality, LOS, a

181 at 3 months, days to achieve 30% decline in SCr, and graft survival.

182 4% vs 13%, P = .008), defined by decrease in SCr level </=1.5 mg/dL.

183 eatment success was defined by a decrease in SCr level to </=1.5 mg/dL for at least 48 hours by day 1

184 Decreases in SCr and survival were correlated (r(2) = .882; P < .001)

185 ession analysis, a dose-related elevation in SCr levels was calculated.

186 idence of in-hospital respiratory failure in SCr of 0.7-0.8 mg/dL and increased in-hospital respirato

187 se to therapy was assessed by improvement in SCr, histologic improvement, and decline in DSA strength

188 ta to assess for WRF defined as: increase in SCr >=0.3 mg/dL, or >=25% decrease in estimated glomerul

189 For example, an increase in SCr >or=0.5 mg/dl was associated with a 6.5-fold (95% co

190 ement in 1/SCr (equivalent to an increase in SCr from 1.0 to 2.0 mg/dl) was associated with a 26% inc

191 ociation with a nearly threefold increase in SCr level.

192 vealed a 0.015 mg/dL (1 mumol/L) increase in SCr levels per 100 mL CM.

193 Time to reach a 50% increase in SCr was directly related to baseline kidney function: Fr

194 t, the time to reach a 0.5-mg/dl increase in SCr was virtually identical after moderate to severe AKI

195 ther an absolute or a percentage increase in SCr.

196 Large increases in SCr concentration were relatively rare (e.g., >or=2.0 mg

197 patients), whereas more modest increases in SCr were common (e.g., >or=0.5 mg/dl in 1237 [13%] patie

198 duction in creatinine clearance, the rise in SCr was 246% with normal baseline kidney function, 174%

199 pressures (interaction P<0.0001); increased SCr best predicted death in patients with right atrial p

200 Iopromide increased SCr from 1.75 mg/dL +/- 0.32 (154.7 micromol/L +/- 28.29

201 (IgM) AECAs did not correlate with increased SCr or incidence of rejection.

202 view, we describe the weaknesses of isolated SCr-based diagnoses, the clinical and molecular subtypin

203 year SCr (regression coefficient=0.02 for ln(SCr), P=0.3; 95%CI: -0.01 to 0.6).

204 Low SCr value at admission is independently associated with

205 roup 2, n=117), and patients with AR but low SCr(6mo) (group 3, n=185).

206 erent among patients without AR and with low SCr(6mo) (group 1, n=376), patients without AR but with

207 For each patient, the lowest SCr (oSCr) observed during the first week was used to es

208 Mean SCr of all groups was similar; however, pTregs were incr

209 Mean SCr was 1.05+/-0.35 mg/dL.

210 le there was an improvement (P=0.02) in mean SCr (2.4 mg/dL) at the end of therapy compared with SCr

211 e of an exogenous marker (reference method), SCr level, age, sex, and height were used to develop a n

212 In IRI mice, SCr level measured at 24, 48, and 72 hr after ischemia c

213 ean 1-week and 1-, 3-, 6-, 12-, and 18-month SCr levels were similar among groups.

214 older fulfilling AKI criteria with 2 or more SCr measurements and 1 or more hs-cTnT measurement.

215 Post-CT AKI with Acute Kidney Injury Network SCr criteria was the primary endpoint.

216 -CT AKI by using Acute Kidney Injury Network SCr criteria; the secondary endpoint was post-CT AKI by

217 defined by using Acute Kidney Injury Network SCr-related criteria.

218 All severe trauma patients with a normal SCr were retrospectively included between January 2005 a

219 old difference between expected and observed SCr that should trigger investigation and potential inte

220 The difference between expected and observed SCr was significantly greater among deceased donor kidne

221 the difference between expected and observed SCr, suggesting that recipient body weight is a major pr

222 ed the expected SCr with the lowest observed SCr in a cohort of living (79) and deceased (67) donor a

223 Expected SCr correlated with the observed SCr in both living and deceased donor kidney recipients,

224 Using eGFR <45 mL/min/1.73 m(2) instead of SCr of >/=1.5 mg/dL would result in a significant but sm

225 Measurement of SCr is practical and offers a simple way to noninvasivel

226 ) after iodixanol (P=0.39), whereas rates of SCr increases > or = 25% were 9.8% and 12.4%, respective

227 Rescue IS was started with rise of SCr/DSA/ rejection.

228 eGFR is associated with an increased risk of SCr-defined AKI following CT examinations.

229 g to the poor sensitivity and specificity of SCr and BUN, we used rat toxicology studies to compare t

230 Threshold of SCr >/=2.0 mg/dL could not be used to identify eGFR <30

231 iants, explaining 0.5% of the variability of SCr in Icelanders in addition to the 1% already accounte

232 Outcome measures were of SCr increase or GFR decrease for 3 days after CT, a SCr

233 ing Global Outcomes AKI definition (based on SCr or CysC).

234 These rare variants have a larger effect on SCr than previously reported common variants, explaining

235 h yielded 38 studies on GL and 18 studies on SCr.

236 h yielded 38 studies on GL and 18 studies on SCr.

237 acement therapy or liver transplantation) or SCr at or above baseline on day 4.

238 Kim-1 outperforms SCr, BUN and urinary NAG in multiple rat models of kidne

239 olute changes in serum creatinine (SCr; peak SCr minus admission SCr) and categorized as no AKI (SCr

240 and relative increases from baseline to peak SCr concentration during hospitalization.

241 e subgroup threshold analysis was performed (SCr <1.5 [<132.60 mumol/L]; >/=1.5 to >/=2.0 mg/dL [>/=1

242 Mean post-SCr increases were significantly less with iopamidol (al

243 The primary outcome was a postdose SCr increase > or = 0.5 mg/dL (44.2 micromol/L) over bas

244 Secondary outcomes were a postdose SCr increase > or = 25%, a postdose estimated glomerular

245 es were observed between pre- and postpartum SCr at longer follow-up intervals.

246 ces were observed between pre and postpartum SCr at longer follow-up intervals.

247 ol/L, a trend toward increased postpregnancy SCr was identified.

248 Pre- and postprocedure SCr levels were assessed.

249 s, hepatic malignancy, elevated preoperative SCr levels, postoperative transition from AKI to AKD, AK

250 In patients with greater prepregnancy SCr and/or drug-treated hypertension during pregnancy, h

251 tions in SLC6A19 that associate with reduced SCr, three of which have been shown to cause Hartnup dis

252 ttransplant function rely on the recipient's SCr and calculations of estimated glomerular filtration

253 sk factor, but not in patients with a stable SCr level less than 1.5 mg/dL.

254 Patients with stable SCr less than 1.5 mg/dL (132.60 mumol/L) were not at ris

255 r data show that, in case of graft survival, SCr remains stable over the years.

256 of eGFR likely captures true GFR better than SCr, especially among women.

257 aneurysm, urinary Fg increased earlier than SCr in patients who developed postoperative AKI (AUC-ROC

258 UC-ROC=0.90), with a performance higher than SCr (AUC-ROC=0.73) and similar to cystatin C (AUC-ROC=0.

259 We predicted that SCr is widely distributed within gram-negative bacteria.

260 The SCr(10d) correlated weakly with graft survival (Cox, P=0

261 The SCr(10d) is an indicator of risk factors from both the d

262 The SCr-defined vs CysC-defined AKI incidence differed subst

263 ressed at 7 days despite suggestion from the SCr value that renal function is improving.

264 alculated that 64% of the variability in the SCr 6mo among patients was due to donor factors and 36%

265 tion we investigated the implications of the SCr(10d) concentration for graft prognosis.

266 In 11 (4.3%) patients, the SCr levels increased more than 25%, but all increases we

267 ith a protective effect against reaching the SCr threshold of 1.6 mg/dL (RR=0.80, P<0.001) beyond 12

268 had AR, that was equal to or higher than the SCr(6mo).

269 of racially dissimilar pairs showed that the SCr 6mo and graft survival 6 months after transplantatio

270 Compared with the SCr-based definition, the CysC-based definition is more

271 These SCr levels correlated with one- and five-year graft surv

272 72 hr and 7 days after ischemia, even though SCr level at 7 days was not different between control an

273 ndpoint was post-CT AKI by using traditional SCr criteria for contrast material-induced nephrotoxicit

274 had a SCr at 10 days after transplantation (SCr(10d)), before they had AR, that was equal to or high

275 reatinine at 6 months after transplantation (SCr(6mo) < or > or = 2 mg/dl).

276 However, at 1 year after transplantation, SCr was 1.4 +/- 0.2 in group I, 2.0 +/- 0.9 in group II,

277 Using SCr threshold of >/=1.5 mg/dL, identified inpatients had

278 Using SCr threshold of >/=2.0 mg/dL, identified inpatients had

279 f skin color on MELD scores calculated using SCr or corrected creatinine (CrC) in female candidates f

280 tion of Diet in Renal Disease formula, using SCr.

281 ailure based on various admission SCr, using SCr of 0.7-0.8 mg/dL as the reference group in the analy

282 sses these issues but overestimates GFR when SCr levels are low.

283 variates: 1/SCr, 1/SCr2, age, and sex (where SCr = serum creatinine).

284 2 patients) with iodixanol (P=0.11), whereas SCr increases > or = 25% were 10.3% and 15.2%, respectiv

285 tional hazards analysis to determine whether SCr was an independent predictor of mortality.

286 enotyped individuals over the age of 18 with SCr measurements.

287 nces and all but one are rare (MAF <2%) with SCr effects between 0.085 and 0.129 standard deviations.

288 We tested the five variants associating with SCr for association with CKD in an Icelandic sample of 1

289 d loss-of-function variants associating with SCr in three solute carriers (SLC6A19, SLC25A45 and SLC4

290 ed the imputed variants for association with SCr.

291 4 mg/dL) at the end of therapy compared with SCr at the time of diagnosis (2.9 mg/dL), this improveme

292 cative of injury often do not correlate with SCr levels.

293 Compared with patients with SCr <1.0 mg/dL, those with SCr 1.0 to 1.4 mg/dL and SCr

294 ith patients with SCr <1.0 mg/dL, those with SCr 1.0 to 1.4 mg/dL and SCr >1.4 mg/dL had an increased

295 5% CI: 0.26-2.7 for group 2 vs. 1) or 1-year SCr (regression coefficient=0.02 for ln(SCr), P=0.3; 95%

296 Mean 3-month and 1-year SCr levels were 1.9 and 1.8, respectively, in the remain